A practical reference on prothymosin alpha: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
A poll found that California voters thought the most important issue for Newsom and the state legislature to work on in 2020 was homelessness. In his first week of office, Newsom threatened to withhold state funding for infrastructure to communities that failed to take actions to alleviate California's housing shortage. In late January 2019, he announced that he would sue Huntington Beach for preventing the construction of affordable housing. A year later, the city acted to settle the lawsuit by the state. Newsom opposes NIMBY (not-in-my-back-yard) sentiment, declaring in 2022 that "NIMBYism is destroying the state". In 2021, he signed a pair of bills into law that made zoning regulations for housing less restrictive, allowing construction of duplexes and fourplexes in lots that were previously zoned exclusively for single-family homes. Newsom also signed a bill that expedites the environmental review process for new multifamily developments worth at least $15,000,000. To participate, developers must apply directly through the governor's office. In 2022, Newsom signed 39 bills into law intended to address California's housing crisis, three of which entailed major land use reform. One bill eliminated minimum parking requirements for housing near mass transit stations throughout the state. Michael Manville, an urban planning professor at UCLA's Luskin School of Public Affairs, called it "one of the biggest land-use reforms in the country".
Many members of the party who had supported Godman reportedly refused to work for Galloway in the next election, including Johann Lamont, who later became Leader of the Scottish Labour Party in 2011. The following August, 13 of the 26 members of the constituency party's executive committee resigned, including Lamont. According to her, Galloway "has done nothing to build bridges with the Members of the Executive [Committee of the Constituency Labour Party] who opposed his selection." She told a journalist from The Guardian: "The quarrel we have is all about accountability, and democracy ... working in harmony, rather than any personal matters." The Labour Party leadership election in 1992 saw Galloway voting for the eventually successful candidates, John Smith for leader and Margaret Beckett as deputy leader. In 1994, after Smith died, Galloway declined to cast a vote in the leadership election (one of only three MPs to do so). In a debate with the leader of the Scottish National Party, Alex Salmond, Galloway responded to one of Salmond's jibes against Labour by declaring "I don't give a fuck what Tony Blair thinks". In 1997, Galloway's Glasgow Hillhead constituency was abolished and, although facing a challenge for the Labour nomination as the candidate for Glasgow Kelvin at the 1997 general election, Galloway defeated Shiona Waldron. He was unchallenged for the nomination for the 2001 general election. He was elected with majorities of 16,643 and 12,014 votes respectively.
=== Phylogeny === It is difficult to reconstruct the early stages in the evolutionary "family tree" of animals using only morphology (their shapes and structures) because of the large differences between the major groups of animals. Hence, reconstructions now rely almost entirely on molecular phylogenetics, which groups organisms based on their biochemistry, most commonly by analyzing DNA or RNA sequences. In 1866, it was proposed that Cnidaria and Ctenophora were more closely related to each other than to Bilateria and formed a group called Coelenterata ("hollow guts") because both rely on the flow of water in and out of a single cavity for feeding, excretion and respiration. In 1881, it was proposed that Ctenophora and Bilateria were more closely related to each other, since they shared features that Cnidaria lack, such as a middle layer of cells (mesoglea in Ctenophora, mesoderm in Bilateria) between the outer and inner layer found in other animals. However, more recent analyses indicate that these similarities were evolved independently in both lineages, instead of being present in their common ancestor. The current view is that Cnidaria and Bilateria are more closely related to each other than either is to Ctenophora. This grouping of Cnidaria and Bilateria has been labelled "Planulozoa", named so because the earliest Bilateria were probably similar to the planula larvae of Cnidaria.
Sources: en.wikipedia.org
== Definitions and investments == In the US, according to investor education materials published by the Financial Industry Regulatory Authority (FINRA) in 2022, the megacap segment is typically (though not officially) defined as stocks with a market cap of at least $200 billion, which is equivalent to at least $213 billion in 2024 using GDP deflator adjustment. Stock Investing For Dummies (2024; 7th edition) gives a definition of megacap which matches FINRA's.
Unlike some brain disorders which have clear molecular hallmarks that can be observed in every affected individual, such as Alzheimer's disease or Parkinson's disease, autism does not have a unifying mechanism at the molecular, cellular, or systems level. The autism spectrum may comprise a small set of disorders that converge on a few common molecular pathways, or it may be a large set of disorders with diverse mechanisms. Autism appears to result from developmental factors that affect many or all functional brain systems. Some factors may disturb the timing of brain development rather than the final product. Listed below are some characteristic findings in ASD brains on molecular and cellular levels regardless of the specific genetic variation or mutation contributing to autism in a particular individual:
The Beauty is an American science fiction body horror television series created by Ryan Murphy and Matthew Hodgson. It is based on the comic book The Beauty, written by Jeremy Haun and Jason A. Hurley, and stars Evan Peters, Anthony Ramos, Jeremy Pope, Rebecca Hall, and Ashton Kutcher. The series premiered on FX and Hulu on January 21, 2026. In July 2026, it was reported that the entire cast had been released so the actors can pursue other projects, leaving the future of the series unclear.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.